Comparing of Aduro BioTech Inc. (ADRO) and Axcella Health Inc. (NASDAQ:AXLA)

Aduro BioTech Inc. (NASDAQ:ADRO) and Axcella Health Inc. (NASDAQ:AXLA), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aduro BioTech Inc. 1 -0.13 54.71M -1.23 0.00
Axcella Health Inc. 5 0.00 7.71M -8.48 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Aduro BioTech Inc. and Axcella Health Inc.

Profitability

Table 2 shows us Aduro BioTech Inc. and Axcella Health Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Aduro BioTech Inc. 5,070,435,588.51% -66.5% -26.3%
Axcella Health Inc. 170,477,159.16% 0% 0%

Analyst Recommendations

In next table is delivered Aduro BioTech Inc. and Axcella Health Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aduro BioTech Inc. 0 0 0 0.00
Axcella Health Inc. 0 0 1 3.00

On the other hand, Axcella Health Inc.’s potential upside is 135.80% and its consensus target price is $11.

Institutional and Insider Ownership

Roughly 47.8% of Aduro BioTech Inc. shares are held by institutional investors while 0% of Axcella Health Inc. are owned by institutional investors. 0.9% are Aduro BioTech Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aduro BioTech Inc. 0% -15.38% -68.65% -51.47% -76.43% -50%
Axcella Health Inc. 15.85% -2.53% 0% 0% 0% -38.55%

For the past year Aduro BioTech Inc. was more bearish than Axcella Health Inc.

Summary

Axcella Health Inc. beats on 6 of the 11 factors Aduro BioTech Inc.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the companyÂ’s products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints; and collaboration agreement with Janssen Biotech, Inc. and Merck. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.